Clinical trials: Cardiomyopathy, Congestive
Congestive Heart Failure, Non-ischemic Cardiomyopathy
Study of the Acute Effects of Triheptanoin in Heart Failure
Patients with dilated cardiomyopathy who present for indwelling right heart catheterization will be enrolled and randomized to either control or triheptanoin oil for five days. Hemodynamics will be assess serially.
- Trial name
- ACETO-TCA (NCT01787851)
- Testing
- Triheptanoin oil
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
BAG3 Mutation Associated Dilated Cardiomyopathy
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
This Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.
- Trial name
- DCMRestore (NCT07218887)
- Testing
- ALXN2350
- Where
- 11 sites in United States, Italy and 2 more
- Volunteers
- 6 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Acute on Chronic Systolic Congestive Heart Failure
Reversible Pulmonary Artery Banding as Simplified Management of End-stage Dilated Left Ventriculopathy in Early Life
The purpose of this study is to: 1) Remodel and restore left ventricular geometry and function. 2) Avoid the need for mechanical circulatory support (MCS) and/or cardiac transplantation (CT).
- Trial name
- NCT02652676
- Testing
- Reversible Pulmonary Artery Banding, GORE-TEX DualMesh EMERGE PLUS Biomaterial
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Loma Linda University
Dilated Cardiomyopathy
A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)
This is a Phase 1 study to determine the safety and efficacy of allogeneic neonatal mesenchymal stromal cells (nMSCs) for the treatment of Dilated Cardiomyopathy.
- Trial name
- NCT06464588
- Testing
- Allogeneic Neonatal mesenchymal stromal cells (nMSCs)
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Emory University
Dilated Cardiomyopathy
Cell Therapy In Dilated Cardiomyopathy
The purpose of this study is to determine effect of cell therapy in patients with severe dilated cardiomyopathy
- Trial name
- NCT00333827
- Testing
- optimal therapy for cardiaca failure, cell
- Where
- Brazil
- Volunteers
- 115 people
- Sponsor
- Ministry of Health, Brazil
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Dilated Cardiomyopathy, Kaposi's Sarcoma-Associated Herpesvirus Infection
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
Evaluating the efficacy of sirolimus (compared to standard therapy alone) in the treatment of dilated cardiomyopathy infected with Kaposi Sarcoma-associated virus -- a multicenter randomized controlled study.
- Trial name
- SDCMK (NCT06236022)
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Tongji Hospital
Hypertension, Congestive Cardiomyopathy
The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution
The primary objective of this study is to study the acute effects of angiotensin-converting enzyme inhibitor (ACEI) on systemic, pulmonary and cerebral blood flow in post bidirectional cavopulmonary connection (BCPC) patients.
- Trial name
- NCT00741156
- Testing
- Enalaprilat
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- The Hospital for Sick Children
Non Ischemic Cardiomyopathy
Inflammatory/Familial Dilated Cardiomyopathy: Is There a Link to Autoimmune Diseases? TP9a
In a hitherto ill-defined proportion of patients with inflammatory/familial cardiomyopathy, the phenotype dilative cardiomyopathy (DCM) is assumed to be the endstage of a multifactorial etiopathogenetic pathophysiology.
- Trial name
- Ikarius (NCT03090425)
- Volunteers
- 320 people
- Sponsor
- Philipps University Marburg
Sudden Cardiac Arrest, Ischemic Cardiomyopathy
Prediction of ARrhythmic Events With Positron Emission Tomography II
Sudden cardiac death continues to be a major contributor to mortality in patients with ischemic cardiomyopathy. While implantable defibrillators can prevent death from ventricular arrhythmias, our current approach to identify…
- Conditions
- Sudden Cardiac Arrest, Ischemic Cardiomyopathy, Congestive Heart Failure
- Trial name
- PAREPET II (NCT03493516)
- Testing
- PET scan quantifying sympathetic denervation using [18F]-LMI1195
- Where
- United States
- Volunteers
- 302 people
- Sponsor
- State University of New York at Buffalo
Symptomatic Genetic Dilated Cardiomyopathy
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM).
- Trial name
- KINSHIP-DCM (NCT07210723)
- Testing
- danicamtiv
- Where
- 78 sites in United States, Belgium and 9 more
- Volunteers
- 332 people
- Sponsor
- Kardigan, Inc.
Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy
DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies
The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP).
- Conditions
- Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy, HCM - Hypertrophic Cardiomyopathy, HOCM - Hypertrophic Obstructive Cardiomyopathy
- Trial name
- TORCH-Plus (NCT04265040)
- Where
- Germany
- Volunteers
- 2,040 people
- Sponsor
- University Hospital Heidelberg
Primary Cardiomyopathy, Dilated Cardiomyopathy
Risk Stratification in Children and Adolescents With Primary Cardiomyopathy
RIKADA is a prospective study performing systematic family screening including clinical and genetic testing in pediatric patients with primary cardiomyopathy and their first-degree relatives with the aim to facilitate risk…
- Conditions
- Primary Cardiomyopathy, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Left Ventricular Noncompaction
- Trial name
- RIKADA (NCT03572569)
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- German Heart Institute
Chronic Heart Failure, Coronary Disease
Role of Endothelial Function, Muscular Fitness and Metabolism in Functional Activity in Patients With Chronic Heart Failure (CHF)
Shortness of breath, fatigue, and exercise intolerance are clinical symptoms of chronic heart failure (CHF). Recent studies suggested that peripheral impairment was the major cause of clinical symptoms, and mechanism may be…
- Conditions
- Chronic Heart Failure, Coronary Disease, Dilated Cardiomyopathy
- Trial name
- NCT01139086
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Lamin A/C Gene Mutation, Dilated Cardiomyopathy, Familial
The Deep Phenotype of Lamin A/C Cardiomyopathy
This study seeks to discover clinically useful tests to improve the diagnosis of a rare and serious heart muscle disease caused by mutations in a gene called 'Lamin'.
- Trial name
- NCT03860454
- Where
- 6 sites in United Kingdom
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University College, London
Indwelling Urinary Catheter Users
Urinary Catheter 'Fill and Flush' Valve: Safety, Effectiveness, Acceptability and Feasibility Trial
The fill and flush valve (valve) is an automated valve which is designed to open in response to rising bladder pressure which occurs as the bladder becomes full.
- Trial name
- NCT04243902
- Testing
- Fill and Flush Valve
- Where
- United Kingdom
- Sponsor
- University of Southampton
Heart Failure, Congestive
Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
The purpose of this study is to determine whether a larger dose of the aldosterone antagonist spironolactone combined with a lower dose of an ACE inhibitor is more effective in reverse left ventricular remodeling in severe…
- Trial name
- NCT00125437
- Testing
- spironolactone
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hebei Medical University
Heart Failure, Dilated Cardiomyopathy
Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality
Primary objective: The primary objective of this study is to determine the efficacy of ICD therapy compared with control on the endpoint of death from any cause.
- Conditions
- Heart Failure, Dilated Cardiomyopathy, Reduced LVEF
- Trial name
- DANISH (NCT00541268)
- Testing
- ICD, Optimal medical treatment
- Where
- 4 sites in Denmark
- Volunteers
- 1,116 people
- Sponsor
- Danish Study Group
Dilated Cardiomyopathy
Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy
The purpose of this study is to determine the safety and clinical effectiveness of umbilical cord mesenchymal cells transplanted by intravenous infusion in patients with heart failure.
- Trial name
- RIMECARD (NCT01739777)
- Testing
- ucMSC, Controls
- Where
- Chile
- Volunteers
- 30 people
- Sponsor
- Universidad de los Andes, Chile
Heart Failure, Congestive, Heart Decompensation
A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest
The purpose of this study is to assess the safety and efficacy of two doses of intravenous NATRECOR® hBNP (a recombinant form of the natural human peptide normally secreted by the heart) versus placebo in the treatment of…
- Trial name
- NCT00288730
- Testing
- nesiritide
- Volunteers
- 127 people
- Sponsor
- Scios, Inc.